amfAR’s public policy office in Washington, D.C., educates policy makers, the media, and the public about evidence-based policies to address HIV/AIDS in the U.S. and around the world.
Harm Reduction/Syringe Services Programs
A Clear Case for Supporting Syringe Services Programs: New Study Shows Relationship Between Public Funding and Lower HIV Incidence
A new study, conducted by Bramson et al. at Mount Sinai Beth Israel in New York City, shows a relationship between public funding of syringe services programs, reducing HIV incidence (the number of new infections in a given year), and maintaining already low HIV incidence among people who inject drugs.
Preventing HIV and Hepatitis C Among People Who Inject Drugs: Public Funding for Syringe Services Programs Makes the Difference
The Centers for Disease Control and Prevention (CDC) estimates that HIV diagnoses among injection drug users (IDU) declined by 70%, from 2002 to 2011. Many attribute this decline to the provision of comprehensive, science-based HIV prevention programs for IDU, including syringe services programs.
Federal Funding for Syringe Services Programs: Saving Money, Promoting Public Safety, and Improving Public Health
According to an overwhelming body of evidence, needle and syringe exchange programs not only reduce the spread of HIV, but also save money, encourage the safe disposal of syringes, minimize the risk of needlestick injuries to law enforcement officials, and help link chemically dependent individuals to vital drug treatment services.
Women and HIV/AIDS in the United States: Fast-Tracking the End of an Epidemic
270,000 women out of a total of 1.2 million Americans are living with HIV and women account for 20% of all new infections.
Women and HIV/AIDS Worldwide: Fast-Tracking the End of an Epidemic
Women comprise half of all adults living with HIV across the globe and represent an even greater proportion of the epidemic in regions such as sub-Saharan Africa (58%) and the Caribbean (53%).
HIV and the Black Community: Do #Black(Gay) lives Matter?
Our nation’s inability to effectively address HIV infections among Black gay men
while making major progress among other heavily impacted populations in the Black community is one of the greatest failures of the U.S. HIV/AIDS response.
Tackling HIV/AIDS Among Key Populations: Essential to Achieving an AIDS-Free Generation
Ending the AIDS epidemic will not be possible without greatly increased efforts to reduce new infections and prevent AIDS-related deaths among key populations at highest risk of HIV acquisition and transmission.
Trans-Pacific Partnership: Curbing Access to Medicines Now and in the Future
The Trans-Pacific Partnership (TPP) is a free trade agreement currently being negotiated
among 12 Pacific Rim countries. It is anticipated
that the agreement will expand existing intellectual property (IP)
protections on pharmaceutical products, which will ultimately
impede access to affordable generic medicines for diseases
such as HIV/AIDS, cancer, tuberculosis, and hepatitis C.
Hepatitis C and Drug Pricing: The Need for a Better Balance
Despite important price reductions for low- and middle-income countries, the astronomical prices being charged for new drugs to treat hepatitis C will inevitably limit access to the drugs, leading to unnecessary loss of life.
Trans Populations and HIV: Time to End the Neglect
Evidence suggests that trans populations may be the most heavily burdened by HIV worldwide. Failure of the global HIV response to meet the needs of this at-risk group is largely the result of widespread stigma, neglect, and institutionalized discrimination.
The Costs of Flat Funding for Biomedical Research
Although the U.S. has long been recognized as the world leader in biomedical research, stagnant funding (which translates into actual funding reductions when adjusted for inflation) imperils U.S. leadership and jeopardizes future life-saving research advances.